AnaptysBio: The Royalty Waterfall Is About To Reverse
AnaptysBio Inc ANAB
$53.36
▼ -3.05%
($-1.68)
🔥 High Short Interest
📅 Earnings This Week
Open
$54.10
Prev Close
$55.04
Day Range
$52.23 – $54.52
52W Range
$11.40 – $72.36
Market Cap
$1.58B
Beta
0.83
EPS (TTM)
$-0.88
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-01-26 |
| Shares Out. | 29,610,000 |
| Website | anaptysbio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 104 |
| Revenue | $25.6M |
| Gross Profit | $25.6M |
| Net Income | -$52.9M |
| Free Cash Flow | $4.4M |
| Total Assets | $329.7M |
| Total Liabilities | $316.9M |
| Equity | $12.7M |
About AnaptysBio Inc
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
AnaptysBio Inc is a publicly traded company under the ticker symbol ANAB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-07-01)